Suzhou, China,, July 26, 2025 / Prnewswire / – The Kintor Pharmaceutical Limited (The “”Business“) is pleased to announce that the phase II stage of the pivot clinical trial of its KX-826 dye developed and potential developed and potential of the first line.
- Regarding efficiency, compared to the placebo group, the BID group (that is to say twice a day) and the BID group of 1.0% have demonstrated statistically significant therapeutic efficiency and clinical meaning. The target zone has non -vellus hair (“Stroke“) On the group of tenders of 0.5% showed an increase of 22.39 hairs / cm2 compared to the base line, the TAHC of the 1.0% auction group showed an increase of 21.87 hairs / cm2 compared to the basic line, the TAHC of the Placebo group showed an increase of 8.73 hair / cm2 from the basic line. (P = 0.002).
Hair growth assessment (“Fake“) The indicators of researchers of 0.5% group of tenders and 1.0% of tenders have both experienced a significant improvement in the placebo group, with a significant therapeutic effect. (P = 0.013).
- In terms of security, the KX-826 dye showed satisfactory security and tolerability in the clinical trial, with a low incidence of global adverse events. No undesirable reactions linked to the sexual dysfunction linked to the drug was observed throughout the study period, which indicated an excellent favorable security profile without observing new security signals.
The results of the analysis were examined by the Independent Data Surveillance Committee (IDMC), and its main recommendation was that the phase III clinical trial of phase III should continue according to current safety and efficiency data, without modification of the processing group or the size of the sample.
Show the original content:https://www.prnewswire.com/apac/News-releases/phase-ii-stage-of-pivotal-clinical-of-kx-8 26-Pienni-1-0-For-The-Treat-Of-Male-Adult-Aga-China-Raided-Primary-Endpoint-302513819.html
Kintor source
